Medical Technology & Devices Analysts, along with a TAVR (Transcatheter Aortic Valve Replacement) implanter, who recently switched to Medtronic, discuss whether Medtronic can take the TAVR share from Edwards Lifesciences on an Analyst/Industry conference call to be held on February 7 at 11 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EW:
- Edwards Lifesciences downgraded to Market Perform from Outperform at Raymond James
- Edwards Lifesciences downgraded to Market Perform at Raymond James
- Early notable gainers among liquid option names on February 1st
- Edwards Lifesciences price target raised to $76 from $68 at Canaccord
- EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS